Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia
•HFNC improves oxygenation in COVID-19.•HFNC decreases the need for intubation and mortality in COVID-19.•HFNC does not change the length of stay in intensive care. In Covid-19 pneumonia, high mortality rates reported in intubated patients have raised non-invasive methods of respiratory support. We...
Gespeichert in:
| Veröffentlicht in: | Heart & lung 2021-05, Vol.50 (3), p.425-429 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 3 |
| container_start_page | 425 |
| container_title | Heart & lung |
| container_volume | 50 |
| creator | Sayan, İsmet Altınay, Mustafa Çınar, Ayşe Surhan Türk, Hacer Şebnem Peker, Nebia Şahin, Kerim Coşkun, Nurcan Demir, Gamze Dilara |
| description | •HFNC improves oxygenation in COVID-19.•HFNC decreases the need for intubation and mortality in COVID-19.•HFNC does not change the length of stay in intensive care.
In Covid-19 pneumonia, high mortality rates reported in intubated patients have raised non-invasive methods of respiratory support.
We aimed to evaluate the impact of HFNC application on intubation requirement, intensive care length of stay, and short-term mortality in patients with COVID-19 pneumonia.
Patients receiving oxygen by reservoir mask or HFNC therapy in our intensive care units due to COVID-19 pneumonia were included in the study. Group H consisted of patients who received HFNC, and Group K consisted of patients who received conventional oxygen therapy (COT). The number of patients intubated, duration of intensive care stay and short-term mortality were recorded.
43 patients were included. The short-term mortality and the number of patients with intubation need was lower in Group H. There was no significant difference between the Groups in the length of intensive care stay.
Administration of HFNC in respiratory failure secondary to COVID-19 pneumonia decreases the need for intubation and mortality. |
| doi_str_mv | 10.1016/j.hrtlng.2021.02.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7874976</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S014795632100039X</els_id><sourcerecordid>2493001765</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-8715fb16b17651af88c1c08929d752bc204bb8865b29eacef373a58bd58023ac3</originalsourceid><addsrcrecordid>eNp9UU2P0zAQjRCILQv_ACEfuaT4I4mdCxIqLFtpxV6AqzVxJq2rxA62U6l_gN-Nqy4LXLBGsuR5783zvKJ4zeiaUda8O6z3IY1ut-aUszXla0rbJ8WK1VyWgiv1tFhRVsmyrRtxVbyI8UDzEY18XlwJ0XCmKroqfm6nGUwifiC3N182BOZ5tAaS9Y7kmnxIMNp0IuB6Yl1CF-0RiYGAZES3S_szNSY45S4BsyQkAeNsAyQfTmQAOy4ZG9F410N-SZ5s7r9vP5asJbPDZfLOwsvi2QBjxFcP93Xx7ebT181teXf_ebv5cFeaqhGpVJLVQ8eajsmmZjAoZZihquVtL2veGU6rrlOqqTveIhgchBRQq66vFeUCjLgu3l9056WbsDfoUoBRz8FO2Zv2YPW_HWf3euePWipZtbLJAm8fBIL_sWBMerLR4DiCQ79EzatWUHq2l6HVBWqCjzHg8DiGUX2OUB_0JUJ9jlBTrnOEmfbmb4uPpN-Z_fkD5kUdLQYdjUVnsLcBTdK9t_-f8AtUNbGW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2493001765</pqid></control><display><type>article</type><title>Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sayan, İsmet ; Altınay, Mustafa ; Çınar, Ayşe Surhan ; Türk, Hacer Şebnem ; Peker, Nebia ; Şahin, Kerim ; Coşkun, Nurcan ; Demir, Gamze Dilara</creator><creatorcontrib>Sayan, İsmet ; Altınay, Mustafa ; Çınar, Ayşe Surhan ; Türk, Hacer Şebnem ; Peker, Nebia ; Şahin, Kerim ; Coşkun, Nurcan ; Demir, Gamze Dilara</creatorcontrib><description>•HFNC improves oxygenation in COVID-19.•HFNC decreases the need for intubation and mortality in COVID-19.•HFNC does not change the length of stay in intensive care.
In Covid-19 pneumonia, high mortality rates reported in intubated patients have raised non-invasive methods of respiratory support.
We aimed to evaluate the impact of HFNC application on intubation requirement, intensive care length of stay, and short-term mortality in patients with COVID-19 pneumonia.
Patients receiving oxygen by reservoir mask or HFNC therapy in our intensive care units due to COVID-19 pneumonia were included in the study. Group H consisted of patients who received HFNC, and Group K consisted of patients who received conventional oxygen therapy (COT). The number of patients intubated, duration of intensive care stay and short-term mortality were recorded.
43 patients were included. The short-term mortality and the number of patients with intubation need was lower in Group H. There was no significant difference between the Groups in the length of intensive care stay.
Administration of HFNC in respiratory failure secondary to COVID-19 pneumonia decreases the need for intubation and mortality.</description><identifier>ISSN: 0147-9563</identifier><identifier>EISSN: 1527-3288</identifier><identifier>DOI: 10.1016/j.hrtlng.2021.02.009</identifier><identifier>PMID: 33621840</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute respiratory failure ; Cannula ; Covid 19 pneumonia ; COVID-19 ; Critical Care ; High flow nasal cannula ; Humans ; Intensive care unit ; Length of Stay ; Oxygen Inhalation Therapy ; Respiratory Insufficiency - etiology ; Respiratory Insufficiency - therapy ; SARS-CoV-2</subject><ispartof>Heart & lung, 2021-05, Vol.50 (3), p.425-429</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><rights>2021 Elsevier Inc. All rights reserved. 2021 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-8715fb16b17651af88c1c08929d752bc204bb8865b29eacef373a58bd58023ac3</citedby><cites>FETCH-LOGICAL-c463t-8715fb16b17651af88c1c08929d752bc204bb8865b29eacef373a58bd58023ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.hrtlng.2021.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33621840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sayan, İsmet</creatorcontrib><creatorcontrib>Altınay, Mustafa</creatorcontrib><creatorcontrib>Çınar, Ayşe Surhan</creatorcontrib><creatorcontrib>Türk, Hacer Şebnem</creatorcontrib><creatorcontrib>Peker, Nebia</creatorcontrib><creatorcontrib>Şahin, Kerim</creatorcontrib><creatorcontrib>Coşkun, Nurcan</creatorcontrib><creatorcontrib>Demir, Gamze Dilara</creatorcontrib><title>Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia</title><title>Heart & lung</title><addtitle>Heart Lung</addtitle><description>•HFNC improves oxygenation in COVID-19.•HFNC decreases the need for intubation and mortality in COVID-19.•HFNC does not change the length of stay in intensive care.
In Covid-19 pneumonia, high mortality rates reported in intubated patients have raised non-invasive methods of respiratory support.
We aimed to evaluate the impact of HFNC application on intubation requirement, intensive care length of stay, and short-term mortality in patients with COVID-19 pneumonia.
Patients receiving oxygen by reservoir mask or HFNC therapy in our intensive care units due to COVID-19 pneumonia were included in the study. Group H consisted of patients who received HFNC, and Group K consisted of patients who received conventional oxygen therapy (COT). The number of patients intubated, duration of intensive care stay and short-term mortality were recorded.
43 patients were included. The short-term mortality and the number of patients with intubation need was lower in Group H. There was no significant difference between the Groups in the length of intensive care stay.
Administration of HFNC in respiratory failure secondary to COVID-19 pneumonia decreases the need for intubation and mortality.</description><subject>Acute respiratory failure</subject><subject>Cannula</subject><subject>Covid 19 pneumonia</subject><subject>COVID-19</subject><subject>Critical Care</subject><subject>High flow nasal cannula</subject><subject>Humans</subject><subject>Intensive care unit</subject><subject>Length of Stay</subject><subject>Oxygen Inhalation Therapy</subject><subject>Respiratory Insufficiency - etiology</subject><subject>Respiratory Insufficiency - therapy</subject><subject>SARS-CoV-2</subject><issn>0147-9563</issn><issn>1527-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU2P0zAQjRCILQv_ACEfuaT4I4mdCxIqLFtpxV6AqzVxJq2rxA62U6l_gN-Nqy4LXLBGsuR5783zvKJ4zeiaUda8O6z3IY1ut-aUszXla0rbJ8WK1VyWgiv1tFhRVsmyrRtxVbyI8UDzEY18XlwJ0XCmKroqfm6nGUwifiC3N182BOZ5tAaS9Y7kmnxIMNp0IuB6Yl1CF-0RiYGAZES3S_szNSY45S4BsyQkAeNsAyQfTmQAOy4ZG9F410N-SZ5s7r9vP5asJbPDZfLOwsvi2QBjxFcP93Xx7ebT181teXf_ebv5cFeaqhGpVJLVQ8eajsmmZjAoZZihquVtL2veGU6rrlOqqTveIhgchBRQq66vFeUCjLgu3l9056WbsDfoUoBRz8FO2Zv2YPW_HWf3euePWipZtbLJAm8fBIL_sWBMerLR4DiCQ79EzatWUHq2l6HVBWqCjzHg8DiGUX2OUB_0JUJ9jlBTrnOEmfbmb4uPpN-Z_fkD5kUdLQYdjUVnsLcBTdK9t_-f8AtUNbGW</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Sayan, İsmet</creator><creator>Altınay, Mustafa</creator><creator>Çınar, Ayşe Surhan</creator><creator>Türk, Hacer Şebnem</creator><creator>Peker, Nebia</creator><creator>Şahin, Kerim</creator><creator>Coşkun, Nurcan</creator><creator>Demir, Gamze Dilara</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210501</creationdate><title>Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia</title><author>Sayan, İsmet ; Altınay, Mustafa ; Çınar, Ayşe Surhan ; Türk, Hacer Şebnem ; Peker, Nebia ; Şahin, Kerim ; Coşkun, Nurcan ; Demir, Gamze Dilara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-8715fb16b17651af88c1c08929d752bc204bb8865b29eacef373a58bd58023ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute respiratory failure</topic><topic>Cannula</topic><topic>Covid 19 pneumonia</topic><topic>COVID-19</topic><topic>Critical Care</topic><topic>High flow nasal cannula</topic><topic>Humans</topic><topic>Intensive care unit</topic><topic>Length of Stay</topic><topic>Oxygen Inhalation Therapy</topic><topic>Respiratory Insufficiency - etiology</topic><topic>Respiratory Insufficiency - therapy</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sayan, İsmet</creatorcontrib><creatorcontrib>Altınay, Mustafa</creatorcontrib><creatorcontrib>Çınar, Ayşe Surhan</creatorcontrib><creatorcontrib>Türk, Hacer Şebnem</creatorcontrib><creatorcontrib>Peker, Nebia</creatorcontrib><creatorcontrib>Şahin, Kerim</creatorcontrib><creatorcontrib>Coşkun, Nurcan</creatorcontrib><creatorcontrib>Demir, Gamze Dilara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Heart & lung</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sayan, İsmet</au><au>Altınay, Mustafa</au><au>Çınar, Ayşe Surhan</au><au>Türk, Hacer Şebnem</au><au>Peker, Nebia</au><au>Şahin, Kerim</au><au>Coşkun, Nurcan</au><au>Demir, Gamze Dilara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia</atitle><jtitle>Heart & lung</jtitle><addtitle>Heart Lung</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>50</volume><issue>3</issue><spage>425</spage><epage>429</epage><pages>425-429</pages><issn>0147-9563</issn><eissn>1527-3288</eissn><abstract>•HFNC improves oxygenation in COVID-19.•HFNC decreases the need for intubation and mortality in COVID-19.•HFNC does not change the length of stay in intensive care.
In Covid-19 pneumonia, high mortality rates reported in intubated patients have raised non-invasive methods of respiratory support.
We aimed to evaluate the impact of HFNC application on intubation requirement, intensive care length of stay, and short-term mortality in patients with COVID-19 pneumonia.
Patients receiving oxygen by reservoir mask or HFNC therapy in our intensive care units due to COVID-19 pneumonia were included in the study. Group H consisted of patients who received HFNC, and Group K consisted of patients who received conventional oxygen therapy (COT). The number of patients intubated, duration of intensive care stay and short-term mortality were recorded.
43 patients were included. The short-term mortality and the number of patients with intubation need was lower in Group H. There was no significant difference between the Groups in the length of intensive care stay.
Administration of HFNC in respiratory failure secondary to COVID-19 pneumonia decreases the need for intubation and mortality.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33621840</pmid><doi>10.1016/j.hrtlng.2021.02.009</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0147-9563 |
| ispartof | Heart & lung, 2021-05, Vol.50 (3), p.425-429 |
| issn | 0147-9563 1527-3288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7874976 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Acute respiratory failure Cannula Covid 19 pneumonia COVID-19 Critical Care High flow nasal cannula Humans Intensive care unit Length of Stay Oxygen Inhalation Therapy Respiratory Insufficiency - etiology Respiratory Insufficiency - therapy SARS-CoV-2 |
| title | Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20HFNC%20application%20on%20mortality%20and%20intensive%20care%20length%20of%20stay%20in%20acute%20respiratory%20failure%20secondary%20to%20COVID-19%20pneumonia&rft.jtitle=Heart%20&%20lung&rft.au=Sayan,%20%C4%B0smet&rft.date=2021-05-01&rft.volume=50&rft.issue=3&rft.spage=425&rft.epage=429&rft.pages=425-429&rft.issn=0147-9563&rft.eissn=1527-3288&rft_id=info:doi/10.1016/j.hrtlng.2021.02.009&rft_dat=%3Cproquest_pubme%3E2493001765%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2493001765&rft_id=info:pmid/33621840&rft_els_id=S014795632100039X&rfr_iscdi=true |